The solute carrier 6 family of transporters

British Journal of Pharmacology

Volumn 167, Issue 2, 2012, Pages 256-278

  Bröer, Stefan ^a   Gether, Ulrik ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

antidepressants; monoamine transporters; transport mechanism; transporter pharmacology

Indexed keywords

1 (4,4 DIPHENYL 3 BUTENYL)NIPECOTIC ACID; 1 [2 (BENZHYDRYLIDENEAMINOOXY)ETHYL] 1,2,5,6 TETRAHYDRO 3 PYRIDINECARBOXYLIC ACID; 1 [2 (BENZHYDRYLOXY)ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE; 2,3 DIAMINOPROPIONIC ACID; 4,5,6,7 TETRAHYDROISOXAZOLO[4,5 C]PYRIDIN 3 OL; AMFEBUTAMONE; AMPHETAMINE; BENZATROPINE; BETA ALANINE; CARRIER PROTEIN; DOPAMINE TRANSPORTER; ESCITALOPRAM; FLUVOXAMINE; HYPOTAURINE; LEUCINE ENKEPHALIN; N [3 (4 FLUOROPHENYL) 3 (4 PHENYLPHENOXY)PROPYL]SARCOSINE; N METHYLTRYPTOPHAN; N(G) METHYLARGININE; NEUROTRANSMITTER; NISOXETINE; NORADRENALIN TRANSPORTER; PIPECOLIC ACID; REBOXETINE; SARCOSINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SOLUTE CARRIER FAMILY 6; TIAGABINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY DISORDER; BIOCHEMISTRY; DEPRESSION; DISEASE ASSOCIATION; DRUG SELECTIVITY; DRUG TARGETING; HOMEOSTASIS; HUMAN; INHIBITION KINETICS; MENTAL DISEASE; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN TRANSPORT; REVIEW; SEIZURE;

AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL TRANSPORT; GENE EXPRESSION REGULATION; HUMANS; MEMBRANE TRANSPORT PROTEINS; NEUROTRANSMITTER AGENTS; PROTEIN CONFORMATION;

EID: 84865425436     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.01975.x     Document Type: Review

References (232)

1. Abramson J, Wright EM, (2009). Structure and function of Na(+)-symporters with inverted repeats. Curr Opin Struct Biol 19: 425-432.
2. Agoston GE, Wu JH, Izenwasser S, George C, Katz J, Kline RH, et al,. (1997). Novel N-substituted 3 alpha-[bis(4'-fluorophenyl)methoxy]tropane analogues: selective ligands for the dopamine transporter. J Med Chem 40: 4329-4339. (Pubitemid 28042312)
3. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-324.
4. Andersen J, Kristensen AS, Bang-Andersen B, Stromgaard K, (2009). Recent advances in the understanding of the interaction of antidepressant drugs with serotonin and norepinephrine transporters. Chem Commun (Camb) 2009: 3677-3692.
5. Andersen J, Stuhr-Hansen N, Zachariassen L, Toubro S, Hansen SM, Eildal JN, et al,. (2011). Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters. Proc Natl Acad Sci USA 108: 12137-12142.
6. Apparsundaram S, Sung U, Price RD, Blakely RD, (2001). Trafficking-dependent and -independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells. J Pharmacol Exp Ther 299: 666-677. (Pubitemid 32979681)
7. Aragon C, Lopez-Corcuera B, (2005). Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion. Trends Pharmacol Sci 26: 283-286. (Pubitemid 40733520)
8. Armsen W, Himmel B, Betz H, Eulenburg V, (2007). The C-terminal PDZ-ligand motif of the neuronal glycine transporter GlyT2 is required for efficient synaptic localization. Mol Cell Neurosci 36: 369-380. (Pubitemid 47633201)
9. Barker EL, Perlman MA, Adkins EM, Houlihan WJ, Pristupa ZB, Niznik HB, et al,. (1998). High affinity recognition of serotonin transporter antagonists defined by species-scanning mutagenesis. An aromatic residue in transmembrane domain I dictates species-selective recognition of citalopram and mazindol. J Biol Chem 273: 19459-19468. (Pubitemid 28366995)
10. Beckman ML, Bernstein EM, Quick MW, (1998). Protein kinase C regulates the interaction between a GABA transporter and syntaxin 1A. J Neurosci 18: 6103-6112. (Pubitemid 28373219)
11. Bettati M, Cavanni P, Di Fabio R, Oliosi B, Perini O, Scheid G, et al,. (2010). Oxa-azaspiro derivatives: a novel class of triple re-uptake inhibitors. ChemMedChem 5: 361-366.
12. Beuming T, Shi L, Javitch JA, Weinstein H, (2006). A comprehensive structure-based alignment of prokaryotic and eukaryotic neurotransmitter/Na+ symporters (NSS) aids in the use of the LeuT structure to probe NSS structure and function. Mol Pharmacol 70: 1630-1642.
13. Beuming T, Kniazeff J, Bergmann ML, Shi L, Gracia L, Raniszewska K, et al,. (2008). The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11: 780-789.
14. Binda F, Dipace C, Bowton E, Robertson SD, Lute BJ, Fog JU, et al,. (2008). Syntaxin 1A interaction with the dopamine transporter promotes amphetamine-induced dopamine efflux. Mol Pharmacol 74: 1101-1108.
15. Bisgaard H, Larsen MA, Mazier S, Beuming T, Newman AH, Weinstein H, et al,. (2011). The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology 60: 182-190.
16. Bjerggaard C, Fog JU, Hastrup H, Madsen K, Loland CJ, Javitch JA, et al,. (2004). Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions. J Neurosci 24: 7024-7036. (Pubitemid 39045459)
17. Blakely RD, Berson HE, Fremeau RT, Jr, Caron MG, Peek MM, Prince HK, et al,. (1991). Cloning and expression of a functional serotonin transporter from rat brain. Nature 354: 66-70. (Pubitemid 21896784)
18. Borden LA, Smith KE, Hartig PR, Branchek TA, Weinshank RL, (1992). Molecular heterogeneity of the gamma-aminobutyric acid (GABA) transport system. Cloning of two novel high affinity GABA transporters from rat brain. J Biol Chem 267: 21098-21104.
19. Borden LA, Dhar TG, Smith KE, Branchek TA, Gluchowski C, Weinshank RL, (1994). Cloning of the human homologue of the GABA transporter GAT-3 and identification of a novel inhibitor with selectivity for this site. Receptors Channels 2: 207-213. (Pubitemid 24325441)
20. Borden LA, Smith KE, Gustafson EL, Branchek TA, Weinshank RL, (1995). Cloning and expression of a betaine/GABA transporter from human brain. J Neurochem 64: 977-984.
21. Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, et al,. (2008). Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 91: 47-58.
22. Bragina L, Marchionni I, Omrani A, Cozzi A, Pellegrini-Giampietro DE, Cherubini E, et al,. (2008). GAT-1 regulates both tonic and phasic GABA(A) receptor-mediated inhibition in the cerebral cortex. J Neurochem 105: 1781-1793. (Pubitemid 351678500)
23. Broer A, Klingel K, Kowalczuk S, Rasko JE, Cavanaugh J, Broer S, (2004). Molecular cloning of mouse amino acid transport system B0, a neutral amino acid transporter related to Hartnup disorder. J Biol Chem 279: 24467-24476. (Pubitemid 38725311)
24. Broer A, Tietze N, Kowalczuk S, Chubb S, Munzinger M, Bak LK, et al,. (2006). The orphan transporter v7-3 (slc6a15) is a Na+-dependent neutral amino acid transporter (B0AT2). Biochem J 393: 421-430. (Pubitemid 43049339)
25. Broer S, (2006). The SLC6 orphans are forming a family of amino acid transporters. Neurochem Int 48: 559-567.
26. Broer S, (2008). Apical transporters for neutral amino acids: physiology and pathophysiology. Physiology (Bethesda) 23: 95-103.
27. Broer S, Bailey CG, Kowalczuk S, Ng C, Vanslambrouck JM, Rodgers H, et al,. (2008). Iminoglycinuria and hyperglycinuria are discrete human phenotypes resulting from complex mutations in proline and glycine transporters. J Clin Invest 118: 3881-3892.
28. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, et al,. (2001). Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871-880. (Pubitemid 34031892)
29. Carboni E, Silvagni A, (2004). Dopamine reuptake by norepinephrine neurons: exception or rule? Crit Rev Neurobiol 16: 121-128. (Pubitemid 39586910)
30. Carroll FI, Kotian P, Dehghani A, Gray JL, Kuzemko MA, Parham KA, et al,. (1995). Cocaine and 3 beta-(4'-substituted phenyl)tropane-2 beta-carboxylic acid ester and amide analogues. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 38: 379-388.
31. Caulfield WL, Collie IT, Dickins RS, Epemolu O, McGuire R, Hill DR, et al,. (2001). The first potent and selective inhibitors of the glycine transporter type 2. J Med Chem 44: 2679-2682. (Pubitemid 32879707)
32. Chen NH, Reith ME, Quick MW, (2004). Synaptic uptake and beyond: the sodium- and chloride-dependent neurotransmitter transporter family SLC6. Pflugers Arch 447: 519-531. (Pubitemid 38241438)
33. Chen R, Tilley MR, Wei H, Zhou F, Zhou FM, Ching S, et al,. (2006). Abolished cocaine reward in mice with a cocaine-insensitive dopamine transporter. Proc Natl Acad Sci USA 103: 9333-9338. (Pubitemid 43902577)
34. Chiu CS, Brickley S, Jensen K, Southwell A, McKinney S, Cull-Candy S, et al,. (2005). GABA transporter deficiency causes tremor, ataxia, nervousness, and increased GABA-induced tonic conductance in cerebellum. J Neurosci 25: 3234-3245. (Pubitemid 40463559)
35. Christiansen B, Meinild AK, Jensen AA, Brauner-Osborne H, (2007). Cloning and characterization of a functional human gamma-aminobutyric acid (GABA) transporter, human GAT-2. J Biol Chem 282: 19331-19341. (Pubitemid 47100093)
36. Clark JA, Deutch AY, Gallipoli PZ, Amara SG, (1992). Functional expression and CNS distribution of a beta-alanine-sensitive neuronal GABA transporter. Neuron 9: 337-348.
37. Clausen RP, Madsen K, Larsson OM, Frolund B, Krogsgaard-Larsen P, Schousboe A, (2006). Structure-activity relationship and pharmacology of gamma-aminobutyric acid (GABA) transport inhibitors. Adv Pharmacol 54: 265-284.
38. Claxton DP, Quick M, Shi L, de Carvalho FD, Weinstein H, Javitch JA, et al,. (2010). Ion/substrate-dependent conformational dynamics of a bacterial homolog of neurotransmitter: sodium symporters. Nat Struct Mol Biol 17: 822-829.
39. Cook EH, Jr, Courchesne R, Lord C, Cox NJ, Yan S, Lincoln A, et al,. (1997). Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 2: 247-250. (Pubitemid 27217689)
40. Cremona ML, Matthies HJ, Pau K, Bowton E, Speed N, Lute BJ, et al,. (2011). Flotillin-1 is essential for PKC-triggered endocytosis and membrane microdomain localization of DAT. Nat Neurosci 14: 469-477.
41. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP, (2005). A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30: 205-211. (Pubitemid 40024415)
42. Danilczyk U, Sarao R, Remy C, Benabbas C, Stange G, Richter A, et al,. (2006). Essential role for collectrin in renal amino acid transport. Nature 444: 1088-1091. (Pubitemid 46018530)
43. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, et al,. (2006). Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318: 657-665. (Pubitemid 44061240)
44. DeFelice LJ, Goswami T, (2007). Transporters as channels. Annu Rev Physiol 69: 87-112. (Pubitemid 46457637)
45. Desai RI, Kopajtic TA, Koffarnus M, Newman AH, Katz JL, (2005). Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J Neurosci 25: 1889-1893. (Pubitemid 40289393)
46. Dhar TG, Borden LA, Tyagarajan S, Smith KE, Branchek TA, Weinshank RL, et al,. (1994). Design, synthesis and evaluation of substituted triarylnipecotic acid derivatives as GABA uptake inhibitors: identification of a ligand with moderate affinity and selectivity for the cloned human GABA transporter GAT-3. J Med Chem 37: 2334-2342. (Pubitemid 24262322)
47. Dodd JR, Christie DL, (2007). Selective amino acid substitutions convert the creatine transporter to a gamma-aminobutyric acid transporter. J Biol Chem 282: 15528-15533. (Pubitemid 47093291)
48. Dohi T, Morita K, Kitayama T, Motoyama N, Morioka N, (2009). Glycine transporter inhibitors as a novel drug discovery strategy for neuropathic pain. Pharmacol Ther 123: 54-79.
49. Dutta AK, Zhang S, Kolhatkar R, Reith ME, (2003). Dopamine transporter as target for drug development of cocaine dependence medications. Eur J Pharmacol 479: 93-106. (Pubitemid 37377879)
50. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT, (2006). Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12: 178-207. (Pubitemid 46047787)
51. Eriksen J, Jorgensen TN, Gether U, (2010). Regulation of dopamine transporter function by protein-protein interactions: new discoveries and methodological challenges. J Neurochem 113: 27-41.
52. Eshleman AJ, Carmolli M, Cumbay M, Martens CR, Neve KA, Janowsky A, (1999). Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. J Pharmacol Exp Ther 289: 877-885. (Pubitemid 29191245)
53. Eulenburg V, Armsen W, Betz H, Gomeza J, (2005). Glycine transporters: essential regulators of neurotransmission. Trends Biochem Sci 30: 325-333. (Pubitemid 40799051)
54. Eulenburg V, Retiounskaia M, Papadopoulos T, Gomeza J, Betz H, (2010). Glial glycine transporter 1 function is essential for early postnatal survival but dispensable in adult mice. Glia 58: 1066-1073.
55. Farhan H, Freissmuth M, Sitte HH, (2006). Oligomerization of neurotransmitter transporters: a ticket from the endoplasmic reticulum to the plasma membrane. Handb Exp Pharmacol 175: 233-249.
56. Farmer MK, Robbins MJ, Medhurst AD, Campbell DA, Ellington K, Duckworth M, et al,. (2000). Cloning and characterization of human NTT5 and v7-3: two orphan transporters of the Na+/Cl- -dependent neurotransmitter transporter gene family. Genomics 70: 241-252. (Pubitemid 32003401)
57. Fog JU, Khoshbouei H, Holy M, Owens WA, Vaegter CB, Sen N, et al,. (2006). Calmodulin kinase II interacts with the dopamine transporter C terminus to regulate amphetamine-induced reverse transport. Neuron 51: 417-429. (Pubitemid 44219035)
58. Forrest LR, Rudnick G, (2009). The rocking bundle: a mechanism for ion-coupled solute flux by symmetrical transporters. Physiology (Bethesda) 24: 377-386.
59. Forrest LR, Tavoulari S, Zhang YW, Rudnick G, Honig B, (2007). Identification of a chloride ion binding site in Na+/Cl -dependent transporters. Proc Natl Acad Sci USA 104: 12761-12766. (Pubitemid 47255228)
60. Forrest LR, Kramer R, Ziegler C, (2011). The structural basis of secondary active transport mechanisms. Biochim Biophys Acta 1807: 167-188.
61. Foster JD, Pananusorn B, Vaughan RA, (2002). Dopamine transporters are phosphorylated on N-terminal serines in rat striatum. J Biol Chem 277: 25178-25186. (Pubitemid 34951824)
62. Fremeau RT, Jr, Caron MG, Blakely RD, (1992). Molecular cloning and expression of a high affinity L-proline transporter expressed in putative glutamatergic pathways of rat brain. Neuron 8: 915-926.
63. Fremeau RT, Jr, Velaz-Faircloth M, Miller JW, Henzi VA, Cohen SM, Nadler JV, et al,. (1996). A novel nonopioid action of enkephalins: competitive inhibition of the mammalian brain high affinity L-proline transporter. Mol Pharmacol 49: 1033-1041. (Pubitemid 26182990)
64. Fukui K, Yang Q, Cao Y, Takahashi N, Hatakeyama H, Wang H, et al,. (2005). The HNF-1 target collectrin controls insulin exocytosis by SNARE complex formation. Cell Metab 2: 373-384.
65. Fuller RW, Snoddy HD, Robertson DW, (1988). Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav 30: 715-721. (Pubitemid 19271158)
66. Gainetdinov RR, Caron MG, (2000). An animal model of attention deficit hyperactivity disorder. Mol Med Today 6: 43-44. (Pubitemid 30010236)
67. Galli A, Blakely RD, DeFelice LJ, (1996). Norepinephrine transporters have channel modes of conduction. Proc Natl Acad Sci USA 93: 8671-8676. (Pubitemid 26269618)
68. Geerlings A, Nunez E, Lopez-Corcuera B, Aragon C, (2001). Calcium- and syntaxin 1-mediated trafficking of the neuronal glycine transporter GLYT2. J Biol Chem 276: 17584-17590.
69. Gether U, Andersen PH, Larsson OM, Schousboe A, (2006). Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 27: 375-383. (Pubitemid 43977787)
70. Gillman PK, (2007). Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 151: 737-748. (Pubitemid 47075311)
71. Giros B, el Mestikawy S, Bertrand L, Caron MG, (1991). Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 295: 149-154.
72. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG, (1996). Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612. (Pubitemid 26052818)
73. Glick SD, Haskew RE, Maisonneuve IM, Carlson JN, Jerussi TP, (2000). Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol 397: 93-102. (Pubitemid 30323815)
74. Goldstein RZ, Woicik PA, Maloney T, Tomasi D, Alia-Klein N, Shan J, et al,. (2010). Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. Proc Natl Acad Sci USA 107: 16667-16672.
75. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI, (2003). The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508. (Pubitemid 37013213)
76. Grunhage F, Schulze TG, Muller DJ, Lanczik M, Franzek E, Albus M, et al,. (2000). Systematic screening for DNA sequence variation in the coding region of the human dopamine transporter gene (DAT1). Mol Psychiatry 5: 275-282. (Pubitemid 30438403)
77. Gu H, Wall SC, Rudnick G, (1994). Stable expression of biogenic amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269: 7124-7130. (Pubitemid 24217896)
78. Gu HH, Wall S, Rudnick G, (1996). Ion coupling stoichiometry for the norepinephrine transporter in membrane vesicles from stably transfected cells. J Biol Chem 271: 6911-6916. (Pubitemid 26104124)
79. Guastella J, Nelson N, Nelson H, Czyzyk L, Keynan S, Miedel MC, et al,. (1990). Cloning and expression of a rat brain GABA transporter. Science 249: 1303-1306.
80. Guastella J, Brecha N, Weigmann C, Lester HA, Davidson N, (1992). Cloning, expression, and localization of a rat brain high-affinity glycine transporter. Proc Natl Acad Sci USA 89: 7189-7193.
81. Guimbal C, Kilimann MW, (1993). A Na(+)-dependent creatine transporter in rabbit brain, muscle, heart, and kidney. cDNA cloning and functional expression. J Biol Chem 268: 8418-8421. (Pubitemid 23118616)
82. Guimbal C, Kilimann MW, (1994). A creatine transporter cDNA from Torpedo illustrates structure/function relationships in the GABA/noradrenaline transporter family. J Mol Biol 241: 317-324. (Pubitemid 24263444)
83. Haenisch B, Linsel K, Bruss M, Gilsbach R, Propping P, Nothen MM, et al,. (2009). Association of major depression with rare functional variants in norepinephrine transporter and serotonin1A receptor genes. Am J Med Genet B Neuropsychiatr Genet 150B: 1013-1016.
84. Hahn MK, Blakely RD, (2007). The functional impact of SLC6 transporter genetic variation. Annu Rev Pharmacol Toxicol 47: 401-441. (Pubitemid 46277034)
85. Hahn MK, Robertson D, Blakely RD, (2003). A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters. J Neurosci 23: 4470-4478. (Pubitemid 36706177)
86. Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, et al,. (1999). Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 22: 239-247. (Pubitemid 29297249)
87. Han DD, Gu HH, (2006). Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6: 6.
88. Hart CL, Haney M, Vosburg SK, Rubin E, Foltin RW, (2008). Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 33: 761-768. (Pubitemid 351252706)
89. Harvey RJ, Topf M, Harvey K, Rees MI, (2008). The genetics of hyperekplexia: more than startle! Trends Genet 24: 439-447.
90. Hatanaka T, Nakanishi T, Huang W, Leibach FH, Prasad PD, Ganapathy V, et al,. (2001). Na+- and Cl- -coupled active transport of nitric oxide synthase inhibitors via amino acid transport system B(0,+). J Clin Invest 107: 1035-1043. (Pubitemid 32323413)
91. Henry LK, Field JR, Adkins EM, Parnas ML, Vaughan RA, Zou MF, et al,. (2006). Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants. J Biol Chem 281: 2012-2023. (Pubitemid 43845789)
92. Henry LK, Meiler J, Blakely RD, (2007). Bound to be different: neurotransmitter transporters meet their bacterial cousins. Mol Interv 7: 306-309.
93. Hoffman BJ, Mezey E, Brownstein MJ, (1991). Cloning of a serotonin transporter affected by antidepressants. Science 254: 579-580. (Pubitemid 21917380)
94. Homberg JR, Lesch KP, (2011). Looking on the bright side of serotonin transporter gene variation. Biol Psychiatry 69: 513-519.
95. Horschitz S, Lau T, Schloss P, (2008). Glycine residues G338 and G342 are important determinants for serotonin transporter dimerisation and cell surface expression. Neurochem Int 52: 770-775.
96. Isaac M, Slassi A, Silva KD, Arora J, MacLean N, Hung B, et al,. (2001). 5,5-Diaryl-2-amino-4-pentenoates as novel, potent, and selective glycine transporter type-2 reuptake inhibitors. Bioorg Med Chem Lett 11: 1371-1373. (Pubitemid 32510823)
97. Iversen L, (2006). Neurotransmitter transporters and their impact on the development of psychopharmacology. Br J Pharmacol 147 (Suppl. 1): S82-S88. (Pubitemid 43077265)
98. Javitt DC, (2009). Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Discov Devel 12: 468-478.
99. Jayanthi LD, Samuvel DJ, Ramamoorthy S, (2004). Regulated internalization and phosphorylation of the native norepinephrine transporter in response to phorbol esters. Evidence for localization in lipid rafts and lipid raft-mediated internalization. J Biol Chem 279: 19315-19326. (Pubitemid 38623363)
100. Just H, Sitte HH, Schmid JA, Freissmuth M, Kudlacek O, (2004). Identification of an additional interaction domain in transmembrane domains 11 and 12 that supports oligomer formation in the human serotonin transporter. J Biol Chem 279: 6650-6657. (Pubitemid 38248803)
101. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, et al,. (2005). Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA 102: 3495-3500. (Pubitemid 40328073)
102. Kanner BI, (2006). Structure and function of sodium-coupled GABA and glutamate transporters. J Membr Biol 213: 89-100. (Pubitemid 46626128)
103. Karakossian MH, Spencer SR, Gomez AQ, Padilla OR, Sacher A, Loo DD, et al,. (2005). Novel properties of a mouse gamma-aminobutyric acid transporter (GAT4). J Membr Biol 203: 65-82. (Pubitemid 40976369)
104. Khoshbouei H, Sen N, Guptaroy B, Johnson L, Lund D, Gnegy ME, et al,. (2004). N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol 2: E78.
105. Kilty JE, Lorang D, Amara SG, (1991). Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 254: 578-579. (Pubitemid 21917379)
106. Kim CH, Hahn MK, Joung Y, Anderson SL, Steele AH, Mazei-Robinson MS, et al,. (2006). A polymorphism in the norepinephrine transporter gene alters promoter activity and is associated with attention-deficit hyperactivity disorder. Proc Natl Acad Sci USA 103: 19164-19169. (Pubitemid 350002844)
107. Kim KM, Kingsmore SF, Han H, Yang-Feng TL, Godinot N, Seldin MF, et al,. (1994). Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes. Mol Pharmacol 45: 608-617. (Pubitemid 24139187)
108. Kleta R, Romeo E, Ristic Z, Ohura T, Stuart C, Arcos-Burgos M, et al,. (2004). Mutations in SLC6A19, encoding B0AT1, cause Hartnup disorder. Nat Genet 36: 999-1002. (Pubitemid 39167498)
109. Kohli MA, Lucae S, Saemann PG, Schmidt MV, Demirkan A, Hek K, et al,. (2011). The Neuronal Transporter Gene SLC6A15 Confers Risk to Major Depression. Neuron 70: 252-265.
110. Kowalczuk S, Broer A, Munzinger M, Tietze N, Klingel K, Broer S, (2005). Molecular cloning of the mouse IMINO system: an Na+- and Cl-dependent proline transporter. Biochem J 386: 417-422. (Pubitemid 40445865)
111. Kowalczuk S, Broer A, Tietze N, Vanslambrouck JM, Rasko JE, Broer S, (2008). A protein complex in the brush-border membrane explains a Hartnup disorder allele. FASEB J 22: 2880-2887.
112. Krishnamurthy H, Gouaux E, (2012). X-ray structures of LeuT in substrate-free outward-open and apo inward-open states. Nature 481: 469-474.
113. Krishnamurthy H, Piscitelli CL, Gouaux E, (2009). Unlocking the molecular secrets of sodium-coupled transporters. Nature 459: 347-355.
114. Kristensen AS, Andersen J, Jorgensen TN, Sorensen L, Eriksen J, Loland CJ, et al,. (2011). SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacol Rev 63: 585-640.
115. Kurian MA, Zhen J, Cheng SY, Li Y, Mordekar SR, Jardine P, et al,. (2009). Homozygous loss-of-function mutations in the gene encoding the dopamine transporter are associated with infantile parkinsonism-dystonia. J Clin Invest 119: 1595-1603.
116. Kvist T, Christiansen B, Jensen AA, Brauner-Osborne H, (2009). The four human gamma-aminobutyric acid (GABA) transporters: pharmacological characterization and validation of a highly efficient screening assay. Comb Chem High Throughput Screen 12: 241-249.
117. Lang F, (2007). Mechanisms and significance of cell volume regulation. J Am Coll Nutr 26 (Suppl. 5): 613S-623S. (Pubitemid 47512057)
118. Larsen MB, Sonders MS, Mortensen OV, Larson GA, Zahniser NR, Amara SG, (2011). Dopamine transport by the serotonin transporter: a mechanistically distinct mode of substrate translocation. J Neurosci 31: 6605-6615.
119. Lechner SM, (2006). Glutamate-based therapeutic approaches: inhibitors of glycine transport. Curr Opin Pharmacol 6: 75-81. (Pubitemid 43103822)
120. Lee KH, Kim MY, Kim DH, Lee YS, (2004). Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopamine transporter. Neurochem Res 29: 1405-1409.
121. Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, et al,. (1996). Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 274: 1527-1531. (Pubitemid 26403928)
122. Leviel V, (2011). Dopamine release mediated by the dopamine transporter, facts and consequences. J Neurochem 118: 475-489.
123. Liu QR, Lopez-Corcuera B, Nelson H, Mandiyan S, Nelson N, (1992a). Cloning and expression of a cDNA encoding the transporter of taurine and beta-alanine in mouse brain. Proc Natl Acad Sci USA 89: 12145-12149. (Pubitemid 23004802)
124. Liu QR, Nelson H, Mandiyan S, Lopez-Corcuera B, Nelson N, (1992b). Cloning and expression of a glycine transporter from mouse brain. FEBS Lett 305: 110-114.
125. Liu QR, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N, (1993a). Cloning and expression of a spinal cord- and brain-specific glycine transporter with novel structural features. J Biol Chem 268: 22802-22808. (Pubitemid 23318342)
126. Liu QR, Mandiyan S, Lopez-Corcuera B, Nelson H, Nelson N, (1993b). A rat brain cDNA encoding the neurotransmitter transporter with an unusual structure. FEBS Lett 315: 114-118. (Pubitemid 23015867)
127. Loland CJ, Desai RI, Zou MF, Cao J, Grundt P, Gerstbrein K, et al,. (2008). Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73: 813-823. (Pubitemid 351397886)
128. Loo DD, Eskandari S, Boorer KJ, Sarkar HK, Wright EM, (2000). Role of Cl- in electrogenic Na+-coupled cotransporters GAT1 and SGLT1. J Biol Chem 275: 37414-37422. (Pubitemid 32004845)
129. Lopez-Corcuera B, Liu QR, Mandiyan S, Nelson H, Nelson N, (1992). Expression of a mouse brain cDNA encoding novel gamma-aminobutyric acid transporter. J Biol Chem 267: 17491-17493.
130. Madsen KK, Clausen RP, Larsson OM, Krogsgaard-Larsen P, Schousboe A, White HS, (2009). Synaptic and extrasynaptic GABA transporters as targets for anti-epileptic drugs. J Neurochem 109 (Suppl. 1): 139-144.
131. Mager S, Sloan J, (2003). Possible role of amino acids, peptides, and sugar transporter in protein removal and innate lung defense. Eur J Pharmacol 479: 263-267. (Pubitemid 37377894)
132. Mager S, Min C, Henry DJ, Chavkin C, Hoffman BJ, Davidson N, et al,. (1994). Conducting states of a mammalian serotonin transporter. Neuron 12: 845-859. (Pubitemid 24126245)
133. Mallorga PJ, Williams JB, Jacobson M, Marques R, Chaudhary A, Conn PJ, et al,. (2003). Pharmacology and expression analysis of glycine transporter GlyT1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine. Neuropharmacology 45: 585-593. (Pubitemid 36980815)
134. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R, (2006). A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol 16: 687-698. (Pubitemid 46175425)
135. Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, et al,. (2004). Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J Physiol 557: 489-500. (Pubitemid 38807389)
136. Masson J, Pohl M, Aidouni Z, Giros B, Hamon M, el Mestikawy S, (1996). The two orphan Na+/Cl(-)-dependent transporters Rxt1 and V-7-3-2 have an overlapping expression pattern in the rat central nervous system. Receptors Channels 4: 227-242. (Pubitemid 27129956)
137. Matskevitch I, Wagner CA, Stegen C, Broer S, Noll B, Risler T, et al,. (1999). Functional characterization of the Betaine/gamma-aminobutyric acid transporter BGT-1 expressed in Xenopus oocytes. J Biol Chem 274: 16709-16716.
138. Mayser W, Schloss P, Betz H, (1992). Primary structure and functional expression of a choline transporter expressed in the rat nervous system. FEBS Lett 305: 31-36.
139. Mazei-Robison MS, Couch RS, Shelton RC, Stein MA, Blakely RD, (2005). Sequence variation in the human dopamine transporter gene in children with attention deficit hyperactivity disorder. Neuropharmacology 49: 724-736. (Pubitemid 41483879)
140. McConathy J, Owens MJ, Kilts CD, Malveaux EJ, Camp VM, Votaw JR, et al,. (2004). Synthesis and biological evaluation of [11C]talopram and [11C]talsupram: candidate PET ligands for the norepinephrine transporter. Nucl Med Biol 31: 705-718. (Pubitemid 38887752)
141. Melikian HE, (2004). Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. Pharmacol Ther 104: 17-27. (Pubitemid 39410560)
142. Minzenberg MJ, Carter CS, (2008). Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33: 1477-1502. (Pubitemid 351684703)
143. Miranda M, Sorkin A, (2007). Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol Interv 7: 157-167. (Pubitemid 47026726)
144. Moltzen EK, Bang-Andersen B, (2006). Serotonin reuptake inhibitors: the corner stone in treatment of depression for half a century-a medicinal chemistry survey. Curr Top Med Chem 6: 1801-1823. (Pubitemid 44383201)
145. Munafo MR, Freimer NB, Ng W, Ophoff R, Veijola J, Miettunen J, et al,. (2009). 5-HTTLPR genotype and anxiety-related personality traits: a meta-analysis and new data. Am J Med Genet B Neuropsychiatr Genet 150B: 271-281.
146. Nash SR, Giros B, Kingsmore SF, Rochelle JM, Suter ST, Gregor P, et al,. (1994). Cloning, pharmacological characterization, and genomic localization of the human creatine transporter. Receptors Channels 2: 165-174. (Pubitemid 24262703)
147. Nash SR, Giros B, Kingsmore SF, Kim KM, el-Mestikawy S, Dong Q, et al,. (1998). Cloning, gene structure and genomic localization of an orphan transporter from mouse kidney with six alternatively-spliced isoforms. Receptors Channels 6: 113-128. (Pubitemid 29057307)
148. Navaroli DM, Stevens ZH, Uzelac Z, Gabriel L, King MJ, Lifshitz LM, et al,. (2011). The Plasma Membrane-Associated GTPase Rin Interacts with the Dopamine Transporter and Is Required for Protein Kinase C-Regulated Dopamine Transporter Trafficking. J Neurosci 31: 13758-13770.
149. Nelson N, (1998). The family of Na+/Cl- neurotransmitter transporters. J Neurochem 71: 1785-1803.
150. Newman AH, Kulkarni S, (2002). Probes for the dopamine transporter: new leads toward a cocaine-abuse therapeutic-A focus on analogues of benztropine and rimcazole. Med Res Rev 22: 429-464.
151. Notredame C, Higgins DG, Heringa J, (2000). T-Coffee: a novel method for fast and accurate multiple sequence alignment. J Mol Biol 302: 205-217.
152. Owens MJ, Knight DL, Nemeroff CB, (2001). Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 50: 345-350. (Pubitemid 32816947)
153. Ozaki N, Goldman D, Kaye WH, Plotnicov K, Greenberg BD, Lappalainen J, et al,. (2003). Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 8: 933-936. (Pubitemid 37421700)
154. Pacholczyk T, Blakely RD, Amara SG, (1991). Expression cloning of a cocaine- and antidepressant-sensitive human noradrenaline transporter. Nature 350: 350-354. (Pubitemid 21912229)
155. Page RD, (1996). TreeView: an application to display phylogenetic trees on personal computers. Comput Appl Biosci 12: 357-358.
156. Parra LA, Baust T, El Mestikawy S, Quiroz M, Hoffman B, Haflett JM, et al,. (2008). The orphan transporter Rxt1/NTT4 (SLC6A17) functions as a synaptic vesicle amino acid transporter selective for proline, glycine, leucine, and alanine. Mol Pharmacol 74: 1521-1532.
157. Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, et al,. (2008). Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology 55: 743-754.
158. Pifl C, Agneter E, Drobny H, Sitte HH, Singer EA, (1999). Amphetamine reverses or blocks the operation of the human noradrenaline transporter depending on its concentration: superfusion studies on transfected cells. Neuropharmacology 38: 157-165. (Pubitemid 29073535)
159. Piscitelli CL, Krishnamurthy H, Gouaux E, (2010). Neurotransmitter/sodium symporter orthologue LeuT has a single high-affinity substrate site. Nature 468: 1129-1132.
160. Quick MW, (2003). Regulating the conducting states of a mammalian serotonin transporter. Neuron 40: 537-549. (Pubitemid 37494703)
161. Quick MW, (2006). The role of SNARE proteins in trafficking and function of neurotransmitter transporters. Handb Exp Pharmacol 175: 181-196.
162. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS, et al,. (1993). Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 90: 2542-2546. (Pubitemid 23078664)
163. Ramamoorthy S, Leibach FH, Mahesh VB, Han H, Yang-Feng T, Blakely RD, et al,. (1994). Functional characterization and chromosomal localization of a cloned taurine transporter from human placenta. Biochem J 300: 893-900. (Pubitemid 24180609)
164. Ramamoorthy S, Shippenberg TS, Jayanthi LD, (2011). Regulation of monoamine transporters: role of transporter phosphorylation. Pharmacol Ther 129: 220-238.
165. Rasola A, Galietta LJ, Barone V, Romeo G, Bagnasco S, (1995). Molecular cloning and functional characterization of a GABA/betaine transporter from human kidney. FEBS Lett 373: 229-233.
166. Rees MI, Harvey K, Pearce BR, Chung SK, Duguid IC, Thomas P, et al,. (2006). Mutations in the gene encoding GlyT2 (SLC6A5) define a presynaptic component of human startle disease. Nat Genet 38: 801-806. (Pubitemid 43980601)
167. Risch N, Herrell R, Lehner T, Liang KY, Eaves L, Hoh J, et al,. (2009). Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. JAMA 301: 2462-2471.
168. Robertson SD, Matthies HJ, Galli A, (2009). A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol 39: 73-80.
169. Romeo E, Dave MH, Bacic D, Ristic Z, Camargo SM, Loffing J, et al,. (2006). Luminal kidney and intestine SLC6 amino acid transporters of B0AT-cluster and their tissue distribution in Mus musculus. Am J Physiol Renal Physiol 290: F376-F383. (Pubitemid 43724991)
170. Roux MJ, Supplisson S, (2000). Neuronal and glial glycine transporters have different stoichiometries. Neuron 25: 373-383.
171. Rudnick G, (1998). Bioenergetics of neurotransmitter transport. J Bioenerg Biomembr 30: 173-185. (Pubitemid 28345699)
172. Rudnick G, (2006). Serotonin transporters-structure and function. J Membr Biol 213: 101-110.
173. Rudnick G, Wall SC, (1992). The molecular mechanism of 'ecstasy'[3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89: 1817-1821.
174. Sacher A, Nelson N, Ogi JT, Wright EM, Loo DD, Eskandari S, (2002). Presteady-State and Steady-State Kinetics and Turnover Rate of the Mouse g-Aminobutyric Acid Transporter (mGAT3). J Membr Biol 190: 57-73. (Pubitemid 36930436)
175. Salomons GS, van Dooren SJ, Verhoeven NM, Cecil KM, Ball WS, Degrauw TJ, et al,. (2001). X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. Am J Hum Genet 68: 1497-1500. (Pubitemid 32510625)
176. Sarker S, Weissensteiner R, Steiner I, Sitte HH, Ecker GF, Freissmuth M, et al,. (2010). The high-affinity binding site for tricyclic antidepressants resides in the outer vestibule of the serotonin transporter. Mol Pharmacol 78: 1026-1035.
177. Schicker K, Uzelac Z, Gesmonde J, Bulling S, Stockner T, Freissmuth M, et al,. (2012). Unifying concept of serotonin transporter-associated currents. J Biol Chem 287: 438-445.
178. Schmid JA, Scholze P, Kudlacek O, Freissmuth M, Singer EA, Sitte HH, (2001). Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells. J Biol Chem 276: 3805-3810.
179. Scholze P, Norregaard L, Singer EA, Freissmuth M, Gether U, Sitte HH, (2002). The role of zinc ions in reverse transport mediated by monoamine transporters. J Biol Chem 277: 21505-21513. (Pubitemid 34952294)
180. Seow HF, Broer S, Broer A, Bailey CG, Potter SJ, Cavanaugh JA, et al,. (2004). Hartnup disorder is caused by mutations in the gene encoding the neutral amino acid transporter SLC6A19. Nat Genet 36: 1003-1007. (Pubitemid 39167499)
181. Serretti A, Kato M, De Ronchi D, Kinoshita T, (2007). Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol. Psychiatry 12: 247-257. (Pubitemid 46328503)
182. Shannon JR, Flattem NL, Jordan J, Jacob G, Black BK, Biaggioni I, et al,. (2000). Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 342: 541-549. (Pubitemid 30117894)
183. Sharpe IA, Gehrmann J, Loughnan ML, Thomas L, Adams DA, Atkins A, et al,. (2001). Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter. Nat Neurosci 4: 902-907. (Pubitemid 32801593)
184. Shi L, Quick M, Zhao Y, Weinstein H, Javitch JA, (2008). The mechanism of a neurotransmitter: sodium symporter-inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell 30: 667-677. (Pubitemid 351815131)
185. Singer D, Camargo SM, Huggel K, Romeo E, Danilczyk U, Kuba K, et al,. (2009). Orphan transporter SLC6A18 is renal neutral amino acid transporter B0AT3. J Biol Chem 284: 19953-19960.
186. Singh SK, Yamashita A, Gouaux E, (2007). Antidepressant binding site in a bacterial homologue of neurotransmitter transporters. Nature 448: 952-956. (Pubitemid 47312772)
187. Sinning S, Musgaard M, Jensen M, Severinsen K, Celik L, Koldso H, et al,. (2010). Binding and orientation of tricyclic antidepressants within the central substrate site of the human serotonin transporter. J Biol Chem 285: 8363-8374.
188. Sitte HH, Huck S, Reither H, Boehm S, Singer EA, Pifl C, (1998). Carrier-mediated release, transport rates, and charge transfer induced by amphetamine, tyramine, and dopamine in mammalian cells transfected with the human dopamine transporter. J Neurochem 71: 1289-1297. (Pubitemid 28390284)
189. Sitte HH, Farhan H, Javitch JA, (2004). Sodium-Dependent neurotransmitter transporters: oligomerization as a determinant of transporter function and trafficking. Mol Interv 4: 38-47. (Pubitemid 38702123)
190. Sloan JL, Mager S, (1999). Cloning and functional expression of a human Na(+) and Cl(-)-dependent neutral and cationic amino acid transporter B(0+). J Biol Chem 274: 23740-23745.
191. Smith G, Ruhland T, Mikkelsen G, Andersen K, Christoffersen CT, Alifrangis LH, et al,. (2004). The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. Bioorg Med Chem Lett 14: 4027-4030. (Pubitemid 38844417)
192. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL, (1992a). Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron 8: 927-935.
193. Smith KE, Borden LA, Wang CH, Hartig PR, Branchek TA, Weinshank RL, (1992b). Cloning and expression of a high affinity taurine transporter from rat brain. Mol Pharmacol 42: 563-569. (Pubitemid 23027616)
194. Smith KE, Fried SG, Durkin MM, Gustafson EL, Borden LA, Branchek TA, et al,. (1995). Molecular cloning of an orphan transporter. A new member of the neurotransmitter transporter family. FEBS Lett 357: 86-92.
195. Sonders MS, Zhu SJ, Zahniser NR, Kavanaugh MP, Amara SG, (1997). Multiple ionic conductances of the human dopamine transporter: the actions of dopamine and psychostimulants. J Neurosci 17: 960-974. (Pubitemid 27043955)
196. Sucic S, El-Kasaby A, Kudlacek O, Sarker S, Sitte HH, Marin P, et al,. (2011). The Serotonin Transporter Is an Exclusive Client of the Coat Protein Complex II (COPII) Component SEC24C. J Biol Chem 286: 16482-16490.
197. Sulzer D, Sonders MS, Poulsen NW, Galli A, (2005). Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75: 406-433. (Pubitemid 40834286)
198. Sung U, Apparsundaram S, Galli A, Kahlig KM, Savchenko V, Schroeter S, et al,. (2003). A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. J Neurosci 23: 1697-1709. (Pubitemid 36314725)
199. Supplisson S, Roux MJ, (2002). Why glycine transporters have different stoichiometries. FEBS Lett 529: 93-101. (Pubitemid 35283917)
200. Sutcliffe JS, Delahanty RJ, Prasad HC, McCauley JL, Han Q, Jiang L, et al,. (2005). Allelic heterogeneity at the serotonin transporter locus (SLC6A4) confers susceptibility to autism and rigid-compulsive behaviors. Am J Hum Genet 77: 265-279. (Pubitemid 41022709)
201. Takanaga H, Mackenzie B, Peng JB, Hediger MA, (2005a). Characterization of a branched-chain amino-acid transporter SBAT1 (SLC6A15) that is expressed in human brain. Biochem Biophys Res Commun 337: 892-900. (Pubitemid 41446998)
202. Takanaga H, Mackenzie B, Suzuki Y, Hediger MA, (2005b). Identification of Mammalian Proline Transporter SIT1 (SLC6A20) with Characteristics of Classical System Imino. J Biol Chem 280: 8974-8984. (Pubitemid 40409589)
203. Tarnok Z, Ronai Z, Gervai J, Kereszturi E, Gadoros J, Sasvari-Szekely M, et al,. (2007). Dopaminergic candidate genes in Tourette syndrome: association between tic severity and 3' UTR polymorphism of the dopamine transporter gene. Am J Med Genet B Neuropsychiatr Genet 144B: 900-905. (Pubitemid 47547991)
204. Tatsumi M, Groshan K, Blakely RD, Richelson E, (1997). Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 340: 249-258. (Pubitemid 28022649)
205. Thomsen C, Sorensen PO, Egebjerg J, (1997). 1-(3-(9H-carbazol-9-yl)-1- propyl)-4-(2-methoxyphenyl)-4-piperidinol, a novel subtype selective inhibitor of the mouse type II GABA-transporter. Br J Pharmacol 120: 983-985. (Pubitemid 27122632)
206. Torres GE, (2006). The dopamine transporter proteome. J Neurochem 97 (Suppl. 1): 3-10.
207. Torres GE, Yao WD, Mohn AR, Quan H, Kim KM, Levey AI, et al,. (2001). Functional interaction between monoamine plasma membrane transporters and the synaptic PDZ domain-containing protein PICK1. Neuron 30: 121-134. (Pubitemid 32441681)
208. Torres GE, Gainetdinov RR, Caron MG, (2003). Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4: 13-25. (Pubitemid 37271085)
209. Uchida S, Kwon HM, Yamauchi A, Preston AS, Marumo F, Handler JS, (1992). Molecular cloning of the cDNA for an MDCK cell Na(+)- and Cl(-)-dependent taurine transporter that is regulated by hypertonicity. Proc Natl Acad Sci USA 89: 8230-8234.
210. Uhl GR, Kitayama S, Gregor P, Nanthakumar E, Persico A, Shimada S, (1992). Neurotransmitter transporter family cDNAs in a rat midbrain library: 'orphan transporters' suggest sizable structural variations. Brain Res Mol Brain Res 16: 353-359. (Pubitemid 23035981)
211. Vandenberg RJ, Shaddick K, Ju P, (2007). Molecular basis for substrate discrimination by glycine transporters. J Biol Chem 282: 14447-14453. (Pubitemid 47100462)
212. Vanslambrouck JM, Broer A, Thavyogarajah T, Holst J, Bailey CG, Broer S, et al,. (2010). Renal imino acid and glycine transport system ontogeny and involvement in developmental iminoglycinuria. Biochem J 428: 397-407.
213. Velaz-Faircloth M, Guadano-Ferraz A, Henzi VA, Fremeau RT, Jr, (1995). Mammalian brain-specific L-proline transporter. Neuronal localization of mRNA and enrichment of transporter protein in synaptic plasma membranes. J Biol Chem 270: 15755-15761.
214. Wallimann T, Tokarska-Schlattner M, Schlattner U, (2011). The creatine kinase system and pleiotropic effects of creatine. Amino Acids 40: 1271-1296.
215. Warskulat U, Flogel U, Jacoby C, Hartwig HG, Thewissen M, Merx MW, et al,. (2004). Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised. FASEB J 18: 577-579.
216. Warskulat U, Heller-Stilb B, Oermann E, Zilles K, Haas H, Lang F, et al,. (2007). Phenotype of the taurine transporter knockout mouse. Methods Enzymol 428: 439-458.
217. Wasserman JC, Delpire E, Tonidandel W, Kojima R, Gullans SR, (1994). Molecular characterization of ROSIT, a renal osmotic stress-induced Na(+)-Cl(-)-organic solute cotransporter. Am J Physiol 267: F688-F694.
218. Wiles AL, Pearlman RJ, Rosvall M, Aubrey KR, Vandenberg RJ, (2006). N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a. J Neurochem 99: 781-786. (Pubitemid 44583437)
219. Wilson AA, Ginovart N, Schmidt M, Meyer JH, Threlkeld PG, Houle S, (2000). Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines. J Med Chem 43: 3103-3110. (Pubitemid 30626767)
220. Wong DT, Bymaster FP, (1995). Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors. Adv Exp Med Biol 363: 77-95.
221. Wong DT, Bymaster FP, (2002). Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype? Prog Drug Res 58: 169-222. (Pubitemid 34464546)
222. Yamashita A, Singh SK, Kawate T, Jin Y, Gouaux E, (2005). Crystal structure of a bacterial homologue of Na(+)/Cl(-)-dependent neurotransmitter transporters. Nature 437: 215-223. (Pubitemid 41294479)
223. Yamauchi A, Uchida S, Kwon HM, Preston AS, Robey RB, Garcia-Perez A, et al,. (1992). Cloning of a Na(+)- and Cl(-)-dependent betaine transporter that is regulated by hypertonicity. J Biol Chem 267: 649-652.
224. Yu XC, Zhang W, Oldham A, Buxton E, Patel S, Nghi N, et al,. (2009). Discovery and characterization of potent small molecule inhibitors of the high affinity proline transporter. Neurosci Lett 451: 212-216.
225. Zaia KA, Reimer RJ, (2009). Synaptic Vesicle Protein NTT4/XT1 (SLC6A17) Catalyzes Na+-coupled Neutral Amino Acid Transport. J Biol Chem 284: 8439-8448.
226. Zhao Y, Terry D, Shi L, Weinstein H, Blanchard SC, Javitch JA, (2010). Single-molecule dynamics of gating in a neurotransmitter transporter homologue. Nature 465: 188-193.
227. Zhao Y, Terry DS, Shi L, Quick M, Weinstein H, Blanchard SC, et al,. (2011). Substrate-modulated gating dynamics in a Na(+)-coupled neurotransmitter transporter homologue. Nature 474: 109-113.
228. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith ME, et al,. (2007). LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317: 1390-1393. (Pubitemid 47417479)
229. Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN, (2009). Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol 16: 652-657.
230. Zhu CB, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD, (2005). p38 MAPK activation elevates serotonin transport activity via a trafficking- independent, protein phosphatase 2A-dependent process. J Biol Chem 280: 15649-15658. (Pubitemid 40616683)
231. Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, et al,. (2009). Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil. J Pharmacol Exp Ther 329: 738-746.
232. Zomot E, Bendahan A, Quick M, Zhao Y, Javitch JA, Kanner BI, (2007). Mechanism of chloride interaction with neurotransmitter: sodium symporters. Nature 449: 726-730. (Pubitemid 47552085)